NCT06614322View on ClinicalTrials.gov

SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Painful Peripheral NeuropathyDiabetic Peripheral Neuropathic Pain (DPN)Chemotherapy Induced Peripheral Neuropathy (CIPN)Idiopathic Peripheral Neuropathy
Interventions
DRUG

Pregabalin

300mg/day pregabalin capsule

DRUG

Duloxetine

60mg/day duloxetine capsule

OTHER

Placebo

Placebo capsule

Trial Locations (5)

14618

University of Rochester, Rochester

15206

University of Pittsburgh, Pittsburgh

23298

VCU Medical Center, Richmond

63110

Washington University School of Medicine, St Louis

02215

Beth Israel Deaconess Medical Center for Autonomic and Peripheral Nerve Disorders, Boston

All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

lead

University of Rochester

OTHER

NCT06614322 - SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy. | Biotech Hunter | Biotech Hunter